Argireline
Also known as: Acetyl Hexapeptide-8, Acetyl Hexapeptide-3, Ac-EEMQRR-NH2, AH8, ARG
Synthetic cosmeceutical hexapeptide; SNARE complex inhibitor / neuromuscular signaling inhibitor
What it is
Argireline is a synthetic peptide used in skincare products to reduce the appearance of facial wrinkles. It works by mildly interfering with the muscle signaling process that causes expression lines, similar in concept to botulinum toxin but much weaker and topical. Not FDA-approved as a drug; widely used as a cosmeceutical ingredient.
The scientific side
Argireline (Ac-EEMQRR-NH2) is a synthetic hexapeptide patterned from the N-terminal end of SNAP-25. Its primary mechanism involves interference with the formation and/or stability of the SNARE protein complex required for Ca2+-dependent exocytosis, thereby inhibiting neurotransmitter release at the neuromuscular junction with a potency reported as similar to botulinum neurotoxin A (BoNT-A), though with much lower efficacy than the neurotoxin (PMID 31811523 — NOTE: citing PMID 18498523). Specifically, it inhibits vesicle docking by preventing formation of the ternary SNARE complex and interfering with catecholamine release. In a 3D-bioengineered human skeletal muscle model, Argireline® Amplified peptide was shown to cause muscle relaxation in both healthy and aged tissue. In animal models, topical application for 6 weeks increased type I collagen fibers and decreased type III collagen fibers in aged mouse skin (PMID 23464592, PMID 23607739). Additional proposed activities identified in zebrafish models include moisturizing, anti-inflammatory, and antioxidant effects.
Class: Synthetic cosmeceutical hexapeptide; SNARE complex inhibitor / neuromuscular signaling inhibitor
Administration & storage
- Administration
- Topical cutaneous application (multiple studiese.g.PMID: 18498523PMID: 23417317PMID: 33151254)Subdermal injection in animal model — rat flap study (PMID: 42675285)Facial injection in a human case report (associated with infection; PMID: 33748252)Iontophoretic transdermal delivery — in vitro human excised skin (PMID: 28150423)PDO thread-mediated intradermal controlled release — proposed protocol (PMID: 38314369)
- Storage
- One study examining Argireline-containing cosmetic formulations noted that the methionine residue in the Argireline sequence is a point of oxidation, and that sample preparation strategy should minimize and monitor methionine oxidation to maintain product stability. Stability of emulsion formulations was evaluated by laboratory analyses, rheology tests, and in vitro release assays. No specific storage temperature or shelf-life conditions were stated in the reviewed abstracts.
- Cautions
- A case of Mycobacterium abscessus infection was reported following facial injection of argireline (acetyl hexapeptide-8) in a 45-year-old woman; erythema, nodules, and abscesses appeared at injection sites after one week. The condition was easily misdiagnosed as common bacterial infection. This represents the first reported such case and highlights infection risk with non-sterile or non-standardized injection procedures.,In a double-blind pilot study (n=19), the anti-wrinkle effect of Argireline added to a hyaluronic acid serum was not statistically significant (p>0.05 for all comparisons), indicating efficacy is not guaranteed.,In vitro cytotoxicity studies showed dose-dependent antiproliferation effects of argireline on HEK-293, IMR-32, and human primary skin fibroblast cells, with significant cytotoxicity observed at concentrations 18- to 10,000-fold higher than doxorubicin IC50 (depending on cell line). However, relevant cosmetic-use concentrations were not directly addressed.,The methionine residue in Argireline is susceptible to oxidation in cosmetic formulations; oxidized forms have been detected in commercial products, raising questions about stability and the active ingredient content of finished goods.,The majority of Ac-EEMQRR-amide applied topically remains on the skin surface or in the stratum corneum (0.54% HGP, 0.22% human), with minimal penetration to epidermis (0.01%) and no detectable dermis penetration in in vitro studies — this limits assumptions about depth of biological activity.,Sterile technique is essential for any injection-related procedures; the above Mycobacterium abscessus case underscores the risk of non-standardized cosmetic injection procedures.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Reduction of facial wrinkles (anti-aging / anti-wrinkle cosmetic use) Mixed
- An O/W emulsion containing 10% Argireline applied to healthy women volunteers reduced wrinkle depth up to 30% upon 30 days of treatment. Argireline inhibited neurotransmitter release and showed no in vivo oral toxicity or primary irritation at high doses. PMID 18498523 Blanes-Mira C et al. Int J Cosmet Sci. 2002.
- RCT in 60 Chinese subjects (3:1 argireline:placebo). Argireline applied twice daily for 4 weeks to peri-orbital wrinkles achieved total anti-wrinkle efficacy of 48.9% vs. 0% in placebo (p<0.01 on objective roughness parameters). PMID 23417317 Wang Y et al. Am J Clin Dermatol. 2013.
- Multicenter study confirmed 48.9% anti-wrinkle efficacy in human subjects and showed improved skin morphology with increased type I and decreased type III collagen fibers in aged mice after twice-daily application for 6 weeks. PMID 23607739 Wang Y et al. J Cosmet Laser Ther. 2013.
- Double-blind pilot study (n=19 women) with Argireline-containing hyaluronic acid serum applied twice daily for 4 weeks found non-significant decrease in wrinkle scores (p>0.05 for all comparisons). Effect of Argireline was not proven statistically. No adverse events, allergic reactions, or skin irritations reported. PMID 38024099 Henseler H. GMS Interdiscip Plast Reconstr Surg DGPW. 2023.
- Serum containing acetyl hexapeptide-8 (among other actives) significantly improved static wrinkle appearance (35–69% clinical scoring improvement over 12 weeks) and dynamic wrinkles (10–13% improvement, all p<0.001) in clinical studies (n=50 and n=42). Ex-vivo study showed increased elastic fibres and collagen. PMID 41668671 Zhu M et al. Int J Cosmet Sci. 2026.
- Treatment of blepharospasm (adjunct to botulinum toxin therapy) Human RCT
- Double-blind, placebo-controlled RCT in 24 blepharospasm patients. Daily topical AH8 showed a trend for longer time until return to baseline Jankovic Blepharospasm Rating Scale after BoNT injection (3.7 months active vs. 3.0 months placebo). One-third of active group had considerable extension of symptom control (3.3–7 PMID 23146065 Lungu C et al. Eur J Neurol. 2013.
- Skin aging biomarker modulation (collagen, elastin, extracellular matrix) — ex vivo and animal Animal studies only
- Topical argireline applied twice daily for 6 weeks to aged D-galactose-induced mice improved histological structure of skin tissue; type I collagen increased (p<0.01), type III decreased (p<0.05). PMID 23464592 Wang Y et al. J Cosmet Laser Ther. 2013.
- Argireline® Amplified peptide caused muscle relaxation in a 3D-bioengineered human skeletal muscle platform, evaluated in both healthy and TNF-α-treated aged tissue models. PMID 34284359 Mestre R et al. Biofabrication. 2021.
- In a rat flap model (n=40 Wistar rats), subdermal injectable Argireline produced a collagen profile indistinguishable from saline control; flap survival did not differ among groups (p=0.327). Injectable Argireline produced no detectable tissue-level effect under tested conditions. PMID 42675285 Acuner B et al. Aesthetic Plast Surg. 2026.
- Moisturizing, anti-inflammatory, and antioxidant activity Animal studies only
- In zebrafish embryo models, acetyl hexapeptide-8 (ARG) reduced water loss, alleviated UVB-induced decrease in skin tightness genes (ELN/COL1a1b), reversed H2O2-induced β-galactosidase activity increase, restored telomerase activity, counteracted oxidative stress and mitochondrial damage, and suppressed LPS-induced neut PMID 40176351 Jiang X et al. J Cosmet Dermatol. 2025.
- Skin scar and wrinkle camouflage / quality improvement in patients with skin disorders Human observational
- Retrospective study in 26 patients with skin disorders (cancer, surgical scars, hidradenitis, aging wrinkles). A gel-cream containing 10% acetyl hexapeptide-8 significantly improved skin hydration, elasticity, sebum, and self-image. No allergic reactions documented. PMID 33151254 Palmieri B et al. Clin Ter. 2020.
- Striae distensae treatment (adjunct to fractional laser) Human observational
- Pilot study (n=10) evaluating peri-procedural tripeptide/hexapeptide serum as adjunct to 1540 nm NAFL for striae distensae. All patients reported subjective improvement; addition of tripeptide/hexapeptide serum increased objective improvement, reduced post-inflammatory hyperpigmentation, and increased patient satisfact PMID 33397562 McGuinn KP et al. Skinmed. 2020.
- Copper(II) ion chelation and cytotoxicity in skin cells (derivatives research) In vitro only
- Argireline and three novel derivatives (AN4, AN5, AN6) were evaluated for Cu(II) chelating properties using potentiometric titration and isothermal titration calorimetry. Cytotoxicity of free peptides and Cu(II) complexes was estimated in human skin cells. Results compared against previously studied AN2 derivative. PMID 37752675 Wyrzykowski D et al. J Pept Sci. 2024.
- Photoaging treatment Mixed
- Systematic review concluded that evidence behind peptides (including Argireline) for photoaging treatment is among the strongest of cosmeceuticals, with most studies achieving Level Ib evidence. Topical peptides can effectively treat photodamaged skin. PMID 39233460 Chan LKW et al. Skin Res Technol. 2024.
- Synergistic transdermal delivery for anti-aging (combined nanoparticle/DES system) Mixed
- A system integrating argireline (ARG), dipeptide diaminobutyryl benzamide diacetate (DDB), and μ-conotoxin (CTX) into nanoparticles (DAC-SAPs) with a ternary deep eutectic solvent (BGP DES) significantly inhibited sodium and calcium channel activity, reduced ACh secretion, and improved skin elasticity and wrinkle param PMID 42202650 Bai D et al. Biomater Adv. 2026.
Safety signals
- Mycobacterium abscessus infection at injection sites following facial argireline (acetyl hexapeptide-8) injection: erythema, nodules, and abscesses in a 45-year-old woman, requiring 5 months of clarithromycin and moxifloxacin treatment. PMID 33748252
- Dose-dependent antiproliferative (cytotoxic) effects of argireline observed in vitro in HEK-293, IMR-32 neuroblastoma, and human primary skin fibroblast cell lines; significant cytotoxicity at high concentrations relative to doxorubicin. PMID 24644551
- Argireline and α-arbutin exhibited cytotoxicity at lower concentrations than Reishi extract in HaCaT human keratinocyte cells (AlamarBlue® assay), suggesting a narrower safety margin compared to the natural extract comparator. PMID 41657122
- Methionine oxidation detected in Argireline in commercial cosmetic creams and sera; oxidized form identified by RP-HPLC/MS, raising concerns about stability and product integrity. PMID 33482052
- Injectable Argireline produced no detectable tissue-level effect on collagen or flap survival in a rat model; increased Substance P expression was observed in botulinum toxin + Argireline combination group but not Argireline alone — tissue-level biological effects of injectable Argireline remain unclear. PMID 42675285
Contraindications
- No specific contraindications are explicitly stated in the reviewed literature. Use of injectable argireline via non-standardized cosmetic procedures has been associated with serious mycobacterial infection; invasive injection routes should be approached with extreme caution and sterile technique. PMID 33748252
Protocol
10% topical, twice daily. Cycle: 4 weeks.
Blends containing this peptide
All studies (29)
- PMID 23146065 Human RCT
Treatment of blepharospasm (adjunct to botulinum toxin therapy) - PMID 33151254 Human observational
Skin scar and wrinkle camouflage / quality improvement in patients with skin disorders - PMID 33397562 Human observational
Striae distensae treatment (adjunct to fractional laser) - PMID 18498523 Mixed
Reduction of facial wrinkles (anti-aging / anti-wrinkle cosmetic use) - PMID 23417317 Mixed
Reduction of facial wrinkles (anti-aging / anti-wrinkle cosmetic use) - PMID 23607739 Mixed
Reduction of facial wrinkles (anti-aging / anti-wrinkle cosmetic use) - PMID 38024099 Mixed
Reduction of facial wrinkles (anti-aging / anti-wrinkle cosmetic use) - PMID 39233460 Mixed
Photoaging treatment - PMID 41668671 Mixed
Reduction of facial wrinkles (anti-aging / anti-wrinkle cosmetic use) - PMID 42202650 Mixed
Synergistic transdermal delivery for anti-aging (combined nanoparticle/DES system) - PMID 16149734
2 mg/cm2 (O/W emulsion containing 10% Ac-EEMQRR-amide), 24-hour exposure Topical (in vitro diffusion cells) (in_vitro) - PMID 17520155
- PMID 23464592 Animal studies only
Skin aging biomarker modulation (collagen, elastin, extracellular matrix) — ex vivo and animal - PMID 24644551
Dose-dependent antiproliferative (cytotoxic) effects of argireline observed in vitro in HEK-293, IMR-32 neuroblastoma, and human primary skin fibroblast cell li - PMID 24754410
- PMID 25497319
Not specified (concentration not stated in abstract) Topical (emulsions applied to porcine ear skin and Franz-type diffusion cells) (in_vitro) - PMID 28150423
10 µg/cm2 iontophoretic dose referenced for Argireline® (Acetyl hexapeptide-3, MW 889 Da); donor concentration 1–10 mg/ml tested Iontophoretic transdermal / pas - PMID 29371611
- PMID 31811523
- PMID 33482052
Methionine oxidation detected in Argireline in commercial cosmetic creams and sera; oxidized form identified by RP-HPLC/MS, raising concerns about stability and - PMID 33748252
Mycobacterium abscessus infection at injection sites following facial argireline (acetyl hexapeptide-8) injection: erythema, nodules, and abscesses in a 45-year - PMID 34284359 Animal studies only
Skin aging biomarker modulation (collagen, elastin, extracellular matrix) — ex vivo and animal - PMID 37752675 In vitro only
Copper(II) ion chelation and cytotoxicity in skin cells (derivatives research) - PMID 38314369
- PMID 38376906
- PMID 39496132
- PMID 40176351 Animal studies only
Moisturizing, anti-inflammatory, and antioxidant activity - PMID 41657122
Argireline and α-arbutin exhibited cytotoxicity at lower concentrations than Reishi extract in HaCaT human keratinocyte cells (AlamarBlue® assay), suggesting a - PMID 42675285 Animal studies only
Skin aging biomarker modulation (collagen, elastin, extracellular matrix) — ex vivo and animal
Frequently asked
What is Argireline and how does it work?
Argireline (Ac-EEMQRR-NH2, also known as acetyl hexapeptide-8) is a synthetic hexapeptide patterned from the N-terminal end of SNAP-25. It inhibits neurotransmitter release at the neuromuscular junction by interfering with the formation and/or stability of the SNARE protein complex required for Ca2+-dependent exocytosis, producing a botulinum toxin-like effect with much lower potency and efficacy than BoNT-A. It is used topically in cosmetic products for its anti-wrinkle activity.
Does Argireline really work for wrinkles?
Evidence is mixed. A randomized, double-blind, placebo-controlled trial (n=60 Chinese subjects) found 48.9% total anti-wrinkle efficacy after twice-daily topical application for 4 weeks vs. 0% in placebo. The original formulation study showed up to 30% wrinkle depth reduction after 30 days in healthy women. However, a separate double-blind pilot study (n=19 women) using Argireline in a hyaluronic acid serum found non-significant wrinkle score changes after 4 weeks (p>0.05 for all comparisons; PMID 38024099). Overall evidence quality for peptides in photoaging has been rated as high (Level Ib) in a systematic review, but individual trial results vary.
What dose of Argireline should I use?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: Published studies have used concentrations of 10% acetyl hexapeptide-8 in O/W emulsions applied topically twice daily (PMID 18498523; PMID 33151254). A pilot blepharospasm trial used daily topical application without specifying concentration. Dosing decisions for therapeutic purposes should be made with a licensed healthcare provider.
Is Argireline safe to inject?
The reviewed literature reports one case of Mycobacterium abscessus infection following facial injection of argireline in a 45-year-old woman, with erythema, nodules, and abscesses appearing one week after injection and requiring 5 months of antibiotic therapy. In a rat flap model, subdermal injectable argireline produced no detectable tissue-level effect on collagen composition or flap survival. Argireline is primarily studied as a topical cosmetic ingredient. I can't recommend injection protocols — please consult a licensed healthcare provider.
Can Argireline penetrate the skin?
Skin penetration studies show that the majority of topically applied acetyl hexapeptide-8 remains on the skin surface or within the stratum corneum. In an in vitro study using O/W emulsion at 10%, 0.54% of the applied dose was found in the stratum corneum of hairless guinea pig skin and 0.22% in human cadaver skin; approximately 0.01% reached the epidermis in both, and no peptide was detected in the dermis. Emulsion type influences penetration: a multiple W/O/W emulsion significantly increased penetration into porcine skin compared to simple O/W or W/O emulsions. Iontophoresis has been shown to increase peptide permeation up to 30-fold relative to passive permeation in vitro.
How does Argireline compare to Botox?
Argireline has a similar mechanism to botulinum neurotoxin A — inhibiting SNARE complex formation to reduce neurotransmitter release — but displays much lower efficacy than the neurotoxin. It is applied topically rather than by injection, does not require a prescription, and is considered a safer, more accessible alternative, though its skin penetration is limited (PMID 24754410; PMID 23417317). A public interest analysis noted 'Argireline' search volume is substantially lower than 'Botox' despite recent increases. A double-blind pilot study concluded that Argireline 'is not deemed to be an alternative treatment to botulinum toxin' based on non-significant results. The two are not directly equivalent in clinical effect.
Can I combine Argireline with botulinum toxin injections?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: A double-blind RCT (n=24) found that daily topical acetyl hexapeptide-8 showed a trend for extending the duration of botulinum toxin effect in blepharospasm patients (3.7 months active vs. 3.0 months placebo; PMID 23146065). Real-world clinician case reports describe topical neuro-peptide serum containing acetyl hexapeptide-8 as complementing BTX-A injections. However, combination use decisions should be made by a licensed healthcare provider.
Are there any side effects or safety concerns with Argireline?
The most serious safety signal in the reviewed literature is a reported case of Mycobacterium abscessus infection following facial argireline injection, requiring 5 months of antibiotic therapy. In cytotoxicity studies, dose-dependent antiproliferative effects were observed in HEK-293, neuroblastoma, and skin fibroblast cell lines at concentrations well above likely cosmetic-use levels. In a HaCaT keratinocyte study, argireline showed cytotoxicity at lower concentrations compared to a natural extract comparator. Methionine oxidation in commercial argireline-containing products has been detected, raising stability concerns. In clinical topical studies, no allergic reactions or significant adverse events were generally documented (PMID 33151254; PMID 38024099; PMID 23146065).
What conditions has Argireline been clinically studied for?
Clinical studies of topical Argireline include: (1) peri-orbital wrinkle reduction in Chinese subjects (RCT, PMID 23417317); (2) blepharospasm management as adjunct to botulinum toxin therapy (pilot RCT, PMID 23146065); (3) scar and wrinkle appearance improvement in patients with skin disorders including cancer-related skin changes (retrospective observational, PMID 33151254); (4) striae distensae treatment as adjunct to fractional laser (pilot study, PMID 33397562); and (5) general anti-aging and skin quality outcomes in combination serums (PMID 41668671; PMID 39496132).
What condition or disease should I use Argireline to treat?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider.